Cargando…

Von Hippel–Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein

Von Hippel–Lindau (VHL) disease is characterized by frequent mutation of VHL protein, a tumor suppressor that functions as the substrate recognition subunit of a Cullin2 RING E3 ligase complex (CRL2(VHL)). CRL2(VHL) plays important roles in oxygen sensing by targeting hypoxia-inducible factor-alpha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frost, Julianty, Rocha, Sonia, Ciulli, Alessio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313594/ https://www.ncbi.nlm.nih.gov/pubmed/34174286 http://dx.doi.org/10.1016/j.jbc.2021.100910

Ejemplares similares

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
por: Diehl, Claudia J., et al.
Publicado: (2022)

Deciphering von Hippel-Lindau (VHL/Vhl)-Associated Pancreatic Manifestations by Inactivating Vhl in Specific Pancreatic Cell Populations
por: Shen, H.-C. Jennifer, et al.
Publicado: (2009)

Hemangioblast: origin of hemangioblastoma in von Hippel-Lindau (VHL) syndrome
por: Wang, Herui, et al.
Publicado: (2018)

The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis
por: Hudler, Petra, et al.
Publicado: (2022)

RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response.
por: Frost, Julianty, et al.
Publicado: (2019)

Von Hippel–Lindau Disease (VHL): Characteristic Lesions with Classic Imaging Findings
por: Bajaj, Suryansh, et al.
Publicado: (2023)

Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
por: Buckley, Dennis L., et al.
Publicado: (2012)

Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
por: Moore, Lee E., et al.
Publicado: (2011)

Expression of Von Hippel – Lindau (VHL) gene mutation in diagnosed cases of renal cell carcinoma
por: Shahzad, Humera, et al.
Publicado: (2014)

The von Hippel–Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform
por: Chesnel, F, et al.
Publicado: (2015)

A novel mutation in the VHL gene in a Chinese family with von Hippel-Lindau disease
por: Wu, Xing, et al.
Publicado: (2018)

Clinical diagnosis, treatment and screening of the VHL gene in three von Hippel-Lindau disease pedigrees
por: Lin, Guobing, et al.
Publicado: (2020)

Surface Probing by Fragment-Based Screening and Computational Methods Identifies Ligandable Pockets on the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
por: Lucas, Xavier, et al.
Publicado: (2018)

Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)
por: Kim, Hyunho, et al.
Publicado: (2021)

Sequencing of Von Hippel-Lindau (VHL) Gene from Genomic DNA for Mutation Detection in Italian Patients
por: Akanni, OE, et al.
Publicado: (2006)

Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel–Lindau Disease
por: Hong, Baoan, et al.
Publicado: (2019)

SUN-194 Adrenal Incidentaloma to Pheochromocytoma (Variant of Unknown Significance of Von Hippel Lindau Syndrome, VHL)
por: Oo, Yin Htwe
Publicado: (2020)

Von-Hippel Lindau (VHL) syndrome with bilateral cerebellar hemangioblastomas and retinal angiomas: A rare presentation
por: Acharya, Abhijit, et al.
Publicado: (2023)

Novel interactions of the von Hippel-Lindau (pVHL) tumor suppressor with the CDKN1 family of cell cycle inhibitors
por: Minervini, Giovanni, et al.
Publicado: (2017)

Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2
por: Okumura, Fumihiko, et al.
Publicado: (2017)

A patient with bilateral pheochromocytoma as part of a Von Hippel-Lindau (VHL) syndrome type 2C
por: Schreinemakers, Jennifer MJ, et al.
Publicado: (2007)

Design and Analysis of a Petri Net Model of the Von Hippel-Lindau (VHL) Tumor Suppressor Interaction Network
por: Minervini, Giovanni, et al.
Publicado: (2014)

A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau
por: Ricketts, Christopher J, et al.
Publicado: (2022)

Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)
por: Soares, Pedro, et al.
Publicado: (2017)

Recurrent lobular capillary hemangiomas in a patient with neurofibromatosis type 1 (NF1) and von Hippel-Lindau syndrome (VHL)
por: Haitz, Karyn, et al.
Publicado: (2015)

Molecular Characterization of a Novel Germline VHL Mutation by Extensive In Silico Analysis in an Indian Family with Von Hippel-Lindau Disease
por: Arunachal, Gautham, et al.
Publicado: (2016)

Inactivation of the tumor suppressor gene von Hippel-Lindau (VHL) in granulocytes contributes to development of liver hemangiomas in a mouse model
por: Bader, Hannah L., et al.
Publicado: (2016)

Expression of von Hippel–Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium
por: Hasegawa, Hisashi, et al.
Publicado: (2017)

Identification of a VHL gene mutation in atypical Von Hippel-Lindau syndrome: genotype–phenotype correlation and gene therapy perspective
por: Tong, Dali, et al.
Publicado: (2021)

Germline mutations in the new E1’ cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma
por: Buffet, Alexandre, et al.
Publicado: (2020)

Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family
por: Patocs, Attila, et al.
Publicado: (2008)

Intra-Familial Phenotypic Heterogeneity and Telomere Abnormality in von Hippel- Lindau Disease: Implications for Personalized Surveillance Plan and Pathogenesis of VHL-Associated Tumors
por: Wang, Jiangyi, et al.
Publicado: (2019)

Intronic mutation of the VHL gene associated with central nervous system hemangioblastomas in two Chinese families with Von Hippel–Lindau disease: case report
por: Liu, Zhen, et al.
Publicado: (2020)

Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
por: Galdeano, Carles, et al.
Publicado: (2014)

An optimized protocol for evaluating pathogenicity of VHL germline variants in patients suspected with von Hippel-Lindau syndrome: Using somatic genome to inform the role of germline variants
por: Koeller, Diane R., et al.
Publicado: (2022)

Von Hippel-Lindau Disease
por: Hes, Frederik J, et al.
Publicado: (2005)

MicroRNA-101 targets von Hippel-Lindau tumor suppressor (VHL) to induce HIF1α mediated apoptosis and cell cycle arrest in normoxia condition
por: Liu, Ning, et al.
Publicado: (2016)

Rho-Associated Kinase 1 (ROCK1) inhibition is Synthetically Lethal with Von Hippel Lindau (VHL) Deficiency in Clear Cell Renal Cell Carcinoma (CC-RCC)
por: Thompson, Jordan M., et al.
Publicado: (2016)

Von Hippel-Lindau Disease and the Eye
por: Karimi, Saeed, et al.
Publicado: (2020)

Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition
por: Frost, Julianty, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8o8ht1548hjnjbj18rjf9ln0m4